Annexin 1 is an anti-inflammatory molecule and has also been described to be a common target of autoantibodies. In this study, we determined whether antibodies against annexin 1 can be detected in sera of patients with cutaneous lupus erythematosus (CLE). Levels of anti-annexin 1 antibodies were evaluated by a new established enzyme-linked immunosorbent assay and found to be significantly higher in sera of patients with CLE when compared to normal healthy donors (NHD). Moreover, the percentage of sera positively tested for anti-annexin 1 antibodies was elevated in patients with CLE when compared to NHD. In particular, the percentage of positive sera for anti-annexin 1 antibodies was significantly higher in patients with discoid lupus erythematosus (DLE); however, disease activity did not correlate with the antibody levels. The results of this study indicate that anti-annexin 1 antibodies in sera of patients with DLE might be a valuable aid in the diagnosis of this subtype.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0625.2010.01145.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of antiphospholipid antibodies in COVID-19 patients: A meta-analysis.
Vascul Pharmacol
December 2024
Department of Geriatric, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310006, Zhejiang Province, China; Zhejiang Provincial Key laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Major Chronic Disease in the Elderly, Hangzhou 310006, Zhejiang Province, China. Electronic address:
Objective: In some reports, antiphospholipid antibodies (aPL) prevalence is higher in COVID-19 patients. This study intended to compare aPL prevalence between COVID-19 patients and healthy controls, and differences in aPL types using meta-analysis.
Methods: This work retrieved published literature about association between COVID-19 and aPL from Embase, Web of Science, PubMed, and The Cochrane Library databases.
Increased levels of antibodies to synaptopodin and annexin 1 in patients with primary podocytopathies.
Front Nephrol
October 2024
Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia.
Article Synopsis
- The study investigated the presence of anti-podocyte antibodies, specifically targeting synaptopodin and annexin 1, in patients with nephrotic syndrome to evaluate their role in diagnosing primary podocytopathies like Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS).
- A total of 72 nephrotic syndrome patients were analyzed, alongside 21 healthy individuals, finding higher antibody levels in MCD and FSGS patients compared to the others, indicating their potential use in diagnosis.
- The combined analysis of both antibody types showed significant diagnostic accuracy (sensitivity of 80.9% and specificity of 81.3%), although these antibody levels did not predict how well patients
Laboratory measurement of autoantibodies to Annexin A1: Review and measurements in health and COVID-19.
Transfus Apher Sci
December 2024
Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands.
Annexin A1, a protein released by neutrophils, is a potent regulator of inflammation in the intact form, but loses this activity when cleaved. The presence of autoantibodies to this protein can impact its function. An immunoassay, developed to measure autoantibodies to Annexin A1 in plasma or serum, has been developed and performances are reported.
View Article and Find Full Text PDFAssociation of Anti-Annexin A5 Antibody With Pregnancy Outcomes: A Cohort Study: Anti-annexin A5 antibody with pregnancy outcomes.
Am J Reprod Immunol
October 2024
Department of Obstetrics and Gynecology, Third Affiliated Hospital of Wenzhou Medical University, Ruian, People's Republic of China.
Objective: This study aims to evaluate the correlation between anti-annexin A5 (aANXA5) antibody in the blood and pregnancy outcomes .
Methods: This study is a retrospective cohort study based on singleton pregnancies of the Third Affiliated Hospital of Wenzhou Medical University from May 2018 to December 2022. Baseline characteristics were collected from all participants.
Criteria and non-criteria antiphospholipid autoantibodies screening in patients with late pregnancy morbidity: A cross-sectional study.
Placenta
September 2024
Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Université de Paris, Paris, France; Université Paris Cité, Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252, Faculté de Médecine site Bichat, Laboratoire d'Excellence Inflamex, Paris, France. Electronic address:
Introduction: Antiphospholipid syndrome (APS) is a cause of pregnancy morbidity. We aim to determine the frequency of criteria and non-criteria anti-phospholipid (aPL) autoantibodies in patients admitted for unexplained fetal death (UFD), pre-eclampsia (PE) and/or fetal growth restriction (FGR).
Methods: All consecutive patients with UFD, PE and/or FGR followed in the department of Obstetrics, Bichat Hospital, University of Paris, Paris, between January 2019 and December 2021 were screened.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!